D&D Pharmatech, a South Korean biotechnology company, has raised a $137 million Series B round from a group of Korean and US investors.
US-based Octave Life Sciences co-led the funding round with Korea’s Smilegate Investment, while InterVest, Magna Investment, and LB Investment participated as well. All of the investors participated...
India’s Innoven Capital, a joint venture between UOB and Temasek Holdings-owned Seviora Holdings, has fractionalised a USD 50m venture debt fund using blockchain and smart contracts.
OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.
Temasek Holdings, A91 Partners, and Kae Capital have invested USD 135m in Indian omnichannel wellness products retailer HealthKart.
Northleaf Capital Partners, a Canada-based asset manager that invests in private equity, private credit, and infrastructure, has opened a Tokyo office to spearhead fundraising activity in Asia and is considering the addition of a Korea presence.